A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
一项针对不可切除胰腺癌脆弱患者的随机 II 期研究，比较全剂量吉西他滨与减量吉西他滨联合白蛋白紫杉醇的疗效 (DPCG-01)
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11035-6
Rasmussen, Louise Skau; Winther, Stine B; Chen, Inna M; Weber, Britta; Ventzel, Lise; Liposits, Gabor; Johansen, Julia Sidenius; Detlefsen, Sönke; Egendal, Ida; Shim, Susy; Christensen, Signe; Pfeiffer, Per; Ladekarl, Morten
